Advertisements
SHARE

The Drugs Controller General of India (DCGI) has given approval to Pune’s Serum Institute of India (SII) to conduct clinical trials of Oxford University-Astra Zeneca COVID-19 vaccine in India.

The SII received approval by the India’s top drug regulator on Sunday after a thorough evaluation based on the recommendations of the Subject Expert Committee on COVID-19.

Also Read – Fauci optimistic about Covid-19 vaccine

In a statement, the Health Ministry said, “Drugs Controller General of India has given approval to Serum Institute of India, Pune to conduct Phase II+III clinical trials of Oxford University-Astra Zeneca COVID-19 vaccine (COVISHIELD) in India.”

Patna: A health worker collects swab samples for COVID-19 testing outside Hotel Patliputra Ashok in Patna on July 29, 2020. (Photo: IANS) by .
Patna: A health worker collects swab samples for COVID-19 testing outside Hotel Patliputra Ashok in Patna on July 29, 2020. (Photo: IANS)

The institute had submitted a application seeking permission for conducting the trial in July last week.

The vaccine candidate is in the midst of Phase II and III clinical trials in the UK, Phase III trials in Brazil, and Phase I and II clinical trials in South Africa.

Advertisements

LEAVE A REPLY

Please enter your comment!
Please enter your name here